Lexicon slams FDA over hearing denial following a CRL for its SGLT2 inhibitor candidate

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.